Eltrombopag - Novartis
Alternative Names: 497115; Eltrombopag olamine; ETB-115; Promacta; Reboredo; Revolade; SB-497115; SB-497115-GRLatest Information Update: 25 Oct 2024
At a glance
- Originator Ligand Pharmaceuticals
- Developer French Innovative Leukemia Organisation; GlaxoSmithKline; Groupe Francophone des Myelodysplasies; GSK; Novartis; Technische Universitat Dresden
- Class Antianaemics; Antineoplastics; Benzoates; Biphenyl compounds; Carboxylic acids; Hydrazines; Pyrazoles; Radioprotectives; Small molecules
- Mechanism of Action Thrombopoietin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Aplastic anaemia; Idiopathic thrombocytopenic purpura; Thrombocytopenia
- Phase III Acute radiation syndrome
- Phase II Acute myeloid leukaemia; Myelodysplastic syndromes; Transplant rejection
- Phase I/II Chronic myelomonocytic leukaemia
Most Recent Events
- 11 Apr 2024 University Children's Hospital Basel in collaboration with Novartis Pharmaceuticals completes a phase II iROM2 trial in Idiopathic thrombocytopenic purpura (Adjunctive treatment, Treatment-naive) in Switzerland (PO) (NCT04812483)
- 22 Sep 2023 Novartis Pharmaceuticals completes the phase II trial in Idiopathic thrombocytopenic purpura (Newly diagnosed, Combination therapy) in Germany (PO) (NCT04346654)
- 17 May 2023 Novartis completes a phase II trial in Aplastic anaemia in China (PO) (NCT03988608)